Research Article| Volume 87, ISSUE 5, SUPPLEMENT 1, S76-S81, November 30, 1989

Download started.


Drug-drug interactions with ciprofloxacin and other fluoroquinolones

  • Ron E. Polk
    Requests for reprints should be addressed to Dr. Ron E. Polk, Antibiotic Research Unit, Box 581, Medical College of Virginia, Richmond, Virginia 23298-0581.
    Department of Pharmacy and Medicine, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Early investigational trials with new quinolone antibiotics revealed two important drug-drug interactions: decreased fluoroquinolone absorption when co-administered with magnesium-aluminum antacids and inhibition of theophylline metabolism. Subsequent studies have investigated the mechanisms of these interactions. With respect to the effect of antacids, the absorption of all quinolones appears to be significantly reduced by antacids containing magnesium and/or aluminum, and concomitant administration must be avoided. Other cations, such as calcium, iron, and probably zinc, appear to interact in a similar manner. Chelation between the quinolone and cation is the most likely mechanism. With respect to the effect on the theophylline metabolism, quinolones inhibit specific cytochrome P-450 isozymes responsible for metabolism of methylxanthines, although there are major differences between the quinolones. Enoxacin is the most potent inhibitor, followed by ciprofloxacin, pefloxacin, norfloxacin, and ofloxacin. Caffeine metabolism is also inhibited, although the clinical significance is uncertain. Case reports describe renal failure associated with concomitant administration of cyclosporine and ciprofloxacin, although controlled trials have not demonstrated an interaction. Enoxacin has little effect on warfarin metabolism, suggesting that other quinolones may not affect warfarin disposition. Case reports of central nervous system toxicity from administration of nonsteroidal anti-inflammatory agents and quinolones need confirmation. Patients should be monitored closely when potential interacting agents are used; it is probable that not all interactions have been identified.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Davey PG
        Overview of drug interactions with the quinolones.
        J Antimicrob Chemother. 1988; 22: 97-107
        • Lode H
        Drug interactions with quinolones.
        Rev Infect Dis. 1988; 10: S132-S136
        • Edwards DJ
        • Bowles SK
        • Svensson CK
        • Rybak M
        Inhibition of drug metabolism by quinolone antibiotics.
        Clin Pharm. 1988; 15: 194-204
        • Wijnands WJA
        • Vree TB
        Interaction between the fluoroquinolones and the bronchodilator theophylline.
        J Antimicrob Chemother. 1988; 22: 109-114
        • Rubinstein E
        • Segev S
        Drug interactions of ciprofloxacin with other non-antibiotic agents.
        Am J Med. 1987; 82: 119-123
        • Fass RJ
        The quinolones.
        Ann Intern Med. 1985; 102: 400-401
        • Hoffken G
        • Borner K
        • Glatzel PD
        • et al.
        Reduced enteral absorption of ciprofloxacin in the presence of antacids.
        Eur J Clin Microbiol. 1985; 4: 345-348
        • Wijnands WJA
        • van Heezwaarden ELA
        • Vree TB
        Enoxacin raises plasma theophylline concentrations.
        Lancet. 1984; II: 108-109
        • Schentag JJ
        • Watson WA
        • Nix DE
        • et al.
        Time dependent interaction between antacids and quinolone antibiotics.
        Clin Pharmacol Ther. 1988; 43 (abstr): 135
        • Nix DE
        • Watson WA
        • Lenar ME
        • et al.
        Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.
        Clin Pharmacol Ther. 1989; (in press)
        • Fleming LW
        • Moreland TA
        • Stewart WK
        • Scott AC
        Ciprofloxacin and antacids.
        Lancet. 1986; II (letter): 294
        • Frost RW
        • Lettieri JT
        • Noe A
        • et al.
        Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability.
        Clin Pharmacol Ther. 1989; 45 (abstr): 165
        • Nix DE
        • Wilton JH
        • Ronald B
        • et al.
        Inhibition of norfloxacin absorption by antacids and sucralfate.
        Rev Infect Dis. 1989; 11: S1096
        • Noyes M
        • Polk M
        Norfloxacin and absorption of magnesium-aluminum.
        Ann Intern Med. 1988; 109: 168-169
        • Yuk JH
        • Nightingale CH
        • Quintiliani R
        • et al.
        Brief report: Absorption of ciprofloxacin administered through a nasogastric or nasoduodenal tube in volunteers and patients receiving enternal nutrition.
        in: Proceedings of Ciprofloxacin: Major Advances in Intravenous and Oral Quinolone Therapy, Naples, Florida1989
        • Allais JM
        • Preheim LC
        • Cuevas TA
        • et al.
        Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections.
        Antimicrob Agents Chemother. 1988; 32: 1327-1330
        • Golper TA
        • Hartstein AI
        • Morthland NH
        • et al.
        Effect of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis.
        Antimicrob Agents Chemother. 1987; 31: 1787-1790
      1. (abstr)American Society for Microbiology: influence of chronic administration of calcium on the bioavailability of oral ciprofloxacin, Houston, TexasProceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1989: 211
        • American Society for Microbiology
        Effect of ferrous sulfate and multivitamins with zinc on the absorption of ciprofloxacin in normal volunteers.
        (abstr)in: Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas1989
        • Fernandes PB
        Mode of action, and in vitro and in vivo activities of the fluoroquinolones.
        J Clin Pharmacol. 1988; 28: 156-168
        • Staib AH
        • Harder S
        • Mieke S
        • et al.
        Gyrase-inhibitors impair caffeine metabolism in man.
        Methods Find Exp Clin Pharmacol. 1987; 9: 193-198
        • Harder S
        • Staib AH
        • Beer C
        • et al.
        4-Quinolones inhibit biotransformation of caffeine.
        Eur J Clin Pharmacol. 1988; 35: 651-656
        • Healy DP
        • Polk RE
        • Kanawati L
        • et al.
        Interaction between oral ciprofloxacin and caffeine in normal volunteers.
        Antimicrob Agents Chemother. 1989; 3: 474-478
        • Smith CR
        The adverse effects of fluoroquinolones.
        J Antimicrob Chemother. 1987; 19: 709-711
        • Harder S
        • Fuhr U
        • Staib AH
        • Wolff T
        Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations.
        Am J Med. 1989; 87: 5A-89S-5A-91S
        • Rogge MC
        • Solomon WR
        • Sedman AJ
        • et al.
        The theophylline-enoxacin interaction. 1. Effect of enoxacin dose size on the theophylline disposition.
        Clin Pharmacol Ther. 1988; 44: 579-587
        • Ludwig E
        • Graber H
        • Szekely E
        • Csiba A
        Metabolic interactions of ciprofloxacin.
        in: Proceedings of Ciprofloxacin: Major Advances in Intravenous and Oral Quinolone Therapy, Naples, Florida1989
        • Edwards DJ
        • Waite NM
        • Svenson CK
        Effect of enoxacin and 4-oxo-enoxacin on antipyrine disposition in the rat.
        Drug Metab Dispos. 1988; 16: 653-655
        • Sarkar M
        • Hunt C
        • Guzelian P
        • et al.
        Inhibition of theophylline metabolism in human liver microsomes by fluoroquinolones.
        (abstr)in: Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Los Angeles, California, Washington, D.C1988: 299
        • Logemann C
        • Ohnaus EE
        Enoxacin, a differential inhibitor of the microsomal liver enzyme system in man.
        (abstr)in: Abstracts of the 2nd International Symposium on New Quinolones, Geneva, Switzerland1988: 139
        • Ludwig E
        • Szekely E
        • Csiba A
        • Grager H
        The effect of ciprofloxacin on antipyrine metabolism.
        J Antimicrob Chemother. 1988; 22: 61-67
        • Elston RA
        • Taylor J
        Possible interaction of ciprofloxacin and cyclosporine A.
        J Antimicrob Chemother. 1988; 22: 679-680
        • Avent CK
        • Krinsky D
        • Kirklin JK
        • et al.
        Synergistic nephrotoxicity due to ciprofloxacin and cysclosporine.
        Am J Med. 1988; 85: 452-453
        • Hooper TL
        • Gould FK
        • Swinburn CR
        • et al.
        Ciprofloxacin: a preferred treatment for Legionella infections in patients receiving cyclosporin A.
        J Antimicrob Chemother. 1988; 22: 952-953
        • Lang J
        • Finay de Villaine JL
        • Garraffo R
        • Touraine JL
        Cyclosporine A pharmacokinetics in renal transplant patients receiving ciprofloxacin.
        Am J Med. 1989; 87: 5A-82S-5A-89S
        • Leor J
        • Levartowsky D
        • Sharon C
        Interaction between nalidixic acid and warfarin.
        Ann Intern Med. 1987; 107 (letter): 601
        • Leor J
        • Matetzki S
        Ofloxacin and warfarin.
        Ann Intern Med. 1988; 109 (letter): 761
        • Linville T
        • Matanin D
        Norfloxacin and warfarin.
        Ann Intern Med. 1989; 110 (letter): 751-752
        • Toon S
        • Hopkins KJ
        • Garstang FM
        • et al.
        Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.
        Clin Pharmacol Ther. 1987; 42: 33-41
        • Morikawa K
        • Nagatao O
        • Kubo S
        • et al.
        Unusual CNS toxic action of new quinolones.
        in: 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New YorkOctober 4 to 7, 1987: 255
        • Segev S
        • Rehari M
        • Rubinstein E
        Quinilones, theophylline, and diclofenec interactions with the gamma-aminobutryic acid receptor.
        Antimicrob Agents chemother. 1988; 32: 1624-1626
        • Baciewicz AM
        • Self T
        Rifampin drug interactions in humans.
        Arch Intern Med. 1984; 144: 1667-1671
        • Barriere S
        • Kaatz GW
        • Seo SM
        Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits.
        Antimicrob Agents Chemother. 1989; 33: 589-590